NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued on Friday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.7 %

NURO stock opened at $4.21 on Friday. The firm’s 50-day moving average price is $4.04 and its two-hundred day moving average price is $3.90. The stock has a market capitalization of $8.59 million, a price-to-earnings ratio of -0.92 and a beta of 2.20. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. The firm had revenue of $0.59 million for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter last year, the firm posted ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.